Category: Dabrafenib and Trametinib Combo

SATURDAY, Sept. 29 (HealthDay News) — Researchers say they’ve discovered a two-drug combination that delays treatment resistance in patients with advanced melanoma. By targeting different points in the same growth-factor pathway, the kinase inhibitor drugs dabrafenib and trametinib postponed the development of drug resistance in patients with BRAF-positive metastatic melanoma, the study authors said. Melanoma…

GlaxoSmithKline Plc (GSK)’s combination of two experimental melanoma medicines slowed the cancer’s progress longer than a single-drug treatment, a study found. Patients taking Glaxo’s dabrafenib and trametinib together delayed tumors from progressing for 9.4 months, compared with 5.8 months for patients taking dabrafenib alone, according to the study of 162 patients. The trial was part…

SATURDAY, Sept. 29 (HealthDay News) — Researchers say they’ve discovered a two-drug combination that delays treatment resistance in patients with advanced melanoma. By targeting different points in the same growth-factor pathway, the kinase inhibitor drugs dabrafenib and trametinib postponed the development of drug resistance in patients with BRAF-positive metastatic melanoma, the study authors said. Melanoma…

MONDAY, Oct. 1 (HealthDay News) — For patients with metastatic melanoma with BRAF V600 mutations, combination therapy with a selective BRAF inhibitor (dabrafenib) and a mitogen-activated protein kinase inhibitor (trametinib) is tolerable and active, according to a study published online Sept. 29 in the New England Journal of Medicine to coincide with presentation at the…

National report — A two-drug combination for metastatic melanoma reduced the odds of progression by 60 percent, demonstrating more effectiveness than monotherapy, according to researchers. The study demonstrated that the BRAF-inhibitor dabrafenib and the MEK-inhibitor trametinib resulted in a median progression-free survival of 9.4 months compared to 5.8 months for patients who received only dabrafenib,…